Akebia Therapeutics (AKBA) Cash from Operations (2013 - 2026)
Akebia Therapeutics (AKBA) posted quarterly Cash from Operations of 21207000.0 for Q1 2026, down 56.08% year-over-year from 48288840.12 in Q1 2025, and down 168.13% quarter-over-quarter from 31129000.0 in Q4 2025.
Akebia Therapeutics (AKBA) Cash from Operations (2013 - 2026) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Cash from Operations for 14 consecutive years, with 21207000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations fell 56.08% year-over-year to 21207000.0; the TTM figure through Mar 2026 stood at 60372000.0 (up 273.41% YoY), while the FY2025 annual figure was 67992000.0, up 267.22% from the prior year.
- Cash from Operations eased to 21207000.0 in Q1 2026 per AKBA's latest filing, from 31129000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 33805000.0 in Q3 2022 and bottomed at 54679000.0 in Q4 2022.
- Historically, Cash from Operations has averaged 5318352.94 across 5 years, with a median of 7167000.0 in 2023.
- Annual changes were most pronounced in 2024 — Cash from Operations slumped 377.38% — and 2025, when it surged 797.02%.
- Akebia Therapeutics' Cash from Operations stood at 54679000.0 in 2022, then soared by 95.78% to 2308000.0 in 2023, then tumbled by 93.5% to 4466000.0 in 2024, then soared by 797.02% to 31129000.0 in 2025, then tumbled by 168.13% to 21207000.0 in 2026.
- Business Quant data shows AKBA's Cash from Operations at 21207000.0 in Q1 2026, 31129000.0 in Q4 2025, and 28105000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 411.00 Mn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 655.00 Mn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 800.69 Mn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 313.60 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 381.80 Mn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 136.40 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 277.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn | 3.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.53 Mn |
| Jun 30, 2026 | 3.53 Mn |
| Mar 31, 2026 | -21.21 Mn |
| Mar 31, 2026 | -21.21 Mn |
| Dec 31, 2025 | 31.13 Mn |
| Dec 31, 2025 | 31.13 Mn |
| Sep 30, 2025 | 28.11 Mn |
| Sep 30, 2025 | 28.11 Mn |
| Jun 30, 2025 | 22.35 Mn |
| Jun 30, 2025 | 22.35 Mn |
| Mar 31, 2025 | -13.59 Mn |
| Mar 31, 2025 | -13.59 Mn |
| Dec 31, 2024 | -4.47 Mn |
| Dec 31, 2024 | -4.47 Mn |
| Sep 30, 2024 | -6.70 Mn |
| Sep 30, 2024 | -6.70 Mn |
| Jun 30, 2024 | -10.07 Mn |
| Jun 30, 2024 | -10.07 Mn |
| Mar 31, 2024 | -19.43 Mn |
| Mar 31, 2024 | -19.43 Mn |